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Transplantation immunity is the state of heightened resistance to a  tissue 
graft which develops after an earlier graft has been broken down. Techniques 
for the detection of transplantation immunity  have been developed by Medawar 
(1, 2) for skin, and by Mitchison (3, 4) for transplantable tumors. Ceils from 
the lymphoid tissue of immunized mice have been shown to possess the power 
of transferring immunity, by Brncic, Hoecker, and Gasic  (5) and Mitchison 
(3, 4) with transplantable tumors, and by Biningham, Brent, and Medawar 
(6) with skin homografts. Evidence has been presented by Billingham,  Brent, 
and Medawar that the immunologically  activated tissue of the donor continues 
to function in the host after transfer; for immunity acquired in this way they 
have coined the term "adoptive immunity." 
The present experiments were carried out with the intention of establishing 
the quantitative conditions of transfer of transplantation immunity to tumors; 
and then to investigate the role of the transferred cells in conferring immunity 
on their hosts.  They have been designed to eliminate antigen transferred with 
the cells, and also preformed antibody, as playing any significant  role in the 
acquired  immunity. They also  bear on  the problem of whether the trans- 
ferred cells continue to function in their hosts, or whether the cells of the host 
are activated. 
The experimental materials have been confined to transplantable tumors in 
the mouse. Transplantation immunity and its conditions of transfer are similar 
for tumors and for normal tissue,  and hence the conclusions are likely to be 
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applicable to grafts of normal tissue. The evidence is now very strong  that 
transplantation  immunity is  not  different in  principle from other  types  of 
immlmity,  and  that  it  shows  particular resemblance to sensitization  of  the 
delayed reaction type (1, 2, 7, 8). The present study of transfer of transplan- 
tation  immunity may therefore be  regarded  as  an  extension of  the  studies 
which have been made of transfer of cells engaged in the production of anti- 
bodies against bacterial antigens, and of cellular transfer of sensitivity ((9-11); 
references to earlier work are given by Billingham, Brent, and Medawar, (5)). 
TABLE I 
Inbred Strains and Tumors 
Strain  Allele at histocom- 
patibility-2 locus  Tumor 
Sarcoma 1:~ (Rreoma)  A 
A.SW 
BALB/C 
C.B6 
C57BL/61Ls 
C57BL/10 
B10.D2 
C57BL/10-H-g  a 
B10.LP 
C57BR/a 
C57L 
C3H 
DBA/2 
D2.W 
LP 
LP.RIII 
s§ 
d* 
4§ 
4" 
b* 
4§ 
b§ 
k* 
b* 
k* 
d* 
Not 4§ 
b* 
Not b§ 
C1498 (mydoid leukemia) 
Bll (flbrosarcoma) 
$778 (fibrosareoma) 
6C3HED (lymphosarcoma) 
* As determined by Snell, Smith, and Gabrlelson (12). Allele  H-g" was formerly referred 
to as H-g  ~, and produces the antigens H-g  '~ and H-g  k. 
~t Hereafter referred to as SAI. 
§ As determined by Dr. G. D. Snell (data unpublished). 
II As determined by Snell and Borges (15). 
Materials and Methods 
Inbred Strains  and  Turaors.--The  tumors and strains of mice used in  this 
work are shown in Table I. The histocompatibility-2 (1t-2) locus of the mouse 
is a locus determining susceptibility and resistance to tumor (and presumably 
also normal tissue) transplants, i.e. a locus controlling isoantigens. Information 
about  this locus has  been used extensively in  the design of the present ex- 
periments. 
Strains A, BALB/C, C57BL/10, C57BL/6Ks, C57BR/a, C57L, C3H, DBA/2, and LP 
are standard  inbred strains (13). Strains C57BL/10, C57BL/6Ks,  and  C57L are  dosdy N.  A.  mTCmSON  159 
related to one another.  Tumors originating in C$?BL/10 normally also take in C57BL/6, 
and ~¢e ~ersa, but C57BL/OKs is a  variant substrain carrying the H-2  ~ allele, and so is re- 
sistant to other C57BL tumors.  C57BL tumors of recent origin do not take in C57L, indi- 
cating that  although both strains have the same H-2 gene, differences must  exist at other 
hlstocompatibility loci. 
Strains, A.SW, BI0.D2, BID.LP, C.BO, D2.W, and LP.RIII are "isogenic resistant lines," 
developed by Dr.  G. D. Snell by back-crossing a  histocompatibility gene onto the genetic 
background  of an  inbred  strain  (14).  The portion of their designation preceding the dot 
indicates the strain with which they are effectively isogenlc, except at one histocompatibiUty 
locus.  All these lines had  been passed  through  at  least 6  back-crosses  (Ii  generations of 
crossing)  at the time of their use. 
Strain C57BL/IO-H-2  d derives from a  mutation in the C57BL/10 strain, and is thought 
to be isogenic with this strain  except at the H-2 locus (15).  C57BL/10-H-2  ~ and  BI0.D2 
therefore have apparently identical genetic constitutions; nevertheless the BII tumor which 
originated in  C57BL/10--H-2  d and  which takes unlformly in this strain was found not to 
grow in BI0.D2 hosts.  Residual differences must therefore exist between these two strains, 
even though both are H-2  ~ and both are thought to be isogenic with C57BL/10 except at 
this locus. 
All the mice were bred in the colony of Dr.  G. D. SneLl, except for strain  C57BL/10- 
H-2  d which was bred in the colony of Dr. P. R. F. Borges, and  strain  C57BL/OKs which 
was bred in the colony of Dr. N. Kaliss. The tumors used are maintained as routine in the 
Roscoe B. Jackson Memorial Laboratory by subcutaneous transplantation,  and transplants 
were made available for this work as needed. 
Tumors were ordinarily transplanted  by trocar subcutaneously into the right flank.  For 
certain purposes  Sarcoma  1  (SAI)  tissue was forced through a  coarse grid, taken up in a 
syringe, and injected through a  19 gauge needle subcutaneously into the tall, following the 
procedure of Andervont (16).  SAI was also converted into, and maintained  as, an  ascites 
tumor, so that counted numbers of cells could be injected subcutaneously into non-suscepti- 
ble mice as a  test of immunity. The ascites tumor was maintained in A hosts by intraperi- 
toneal transfer of approximately 3  X  106 cells at intervals of 7,  8,  or 9 days.  For subcu- 
taneous injection, ascitic fluid was withdrawn from the peritoneum,  diluted with an equal 
volume of isotonic sodium citrate,  and  counted in a  standard  hemocytometer.  An appro- 
priate dilution was then made up by the addition of isotonic citrate. 
Lym/~h Node  and  S~leen  T,  ansfer.--For  tmnder of regional lymph node ceils after sub- 
cutaneous  implantation  of tumor  in  the flank,  the sx.illary,  brachlal,  and  inguinal  nodes 
from the side of implantation were taken.  The nodes were trimmed free of fat and  were 
bathed in Ringer solution. The Ringer solution used for bathing lymph nodes and for sus- 
pending lymph node cells contained 1 ml. of McIlvalne's buffer (pH 7.2) and 1 nil. of stock 
glucose solution (600  mg./ml.) for every 100 ml. of medium (17).  Nodes were occasionally 
found  overgrown by tumor,  and were then not transferred.  Some, and  occasionally all, of 
the regional lymph nodes showed marked hypertrophy after a foreign tumor had been grow- 
ing for a  few days,  and  greatly  enlarged lymphatic  ducts could frequently be seen.  For 
transfer  of normal  lymph node  cells,  the axiflary,  brachial,  inguinal,  and  two  superficial 
cervical nodes were taken from both sides of each donor. The weight of this tissue is nearly 
equal to the weight, per donor, of the lymph nodes draining a  9 day old tumor homograft. 
Lymph node cells were transferred  as a  tissue mince, by collecting sufficient nodes for 
transfer into a  single host and chopping them finely with scissors.  A little Ringer solution 
was then drawn up into a 0.25 mi. syringe with the nozzle bored out to a diameter of 1 ram., 
and the mince drawn up and injected through a  19 gauge needle into the peritoneum of the 
host.  Lymph node  cells were also transferred  as  a  suspension;  pooled  minced  nodes was 
transferred  onto  a  metal  seive  (holes  0.0055  X  0.0055  inch,  as  used  by  Snell  (17)), 160  rM~rUNOLOGICAL  RESPONSE  TO  TUMOR  TRANSPLANTS.  I 
and washed through with Ringer solution, allowing 1 mi. fluid for each 6 nodes. The result- 
ing suspension consisted largely of single ceils, and appeared in Giemsa-stained sections to 
comprise more than 95 per cent of lymphocytes. The cells were counted  in a hemocytome- 
ter, and appropriate  quantities  injected intraperitoneally. 
The same  procedure was  used  for the  transfer  of spleen as for minced  lymph nodes. 
Lymph nodes were regularly  transferred  at a  dosage of 4 donors per host,  and were well 
tolerated.  With the equivalent  weight  of spleen, a  dosage of 1 donor per host, the hosts 
often looked sickly, and a mortality as high as 3 deaths  in 28 animals occurred in one ex- 
periment. 
EXPERIMENTAL 
The Survival Time of Tumor Homografts 
Accurate information  on the  time  of breakdown  of homografts provides a 
scale against which the immunological reactions of the host can be measured. 
TABLE  II 
Speed of Breakdown of Tumor Horaografls 
(a)  Sal  in  non-immuuized  C57BR/a  mice 
age of graft, days ................... 
Proportion of grafts alive ............. 
(b)  Sal  in  immlm~zed  C57BR/a  mice 
age of graft, days .................. 
Proportion  of grafts alive .............. 
(0 C1498 in non-immunized  B10.D2  mice 
age of graft, days ................... 
Proportion  of grafts alive .............. 
4  1 
lO/lO 
1/2 
lO/1O 
5 
lO/I0 
8 
9/lO 
1 
lO/lO 
lO 
6/10 
12 
1/lO 
2 
lO/lO 
15 
o/lo 
16 
1/lO 
4 
9/10 
2O 
i/IO 
2O 
O/lO 
6 
S/lO 
25 
o/io 
8 
0/10 
The  timing  also  provides  a  means  of  distinguishing  immunized  from  non- 
immunized  animals,  for  grafts  in  immunized  hosts  are  broken  down  more 
rapidly  (4,  6).  The  survival  time  of  SA1  in  normal  C57BR/a  hosts  and  of 
C1498 in normal B10.D2  hosts was therefore  measured,  following the proce- 
dure  described  in  an  earlier  paper  (4).  The  survival  time  of  SA1  was  also 
measured  in  C57BR/a  hosts  immunized  by  a  graft  of  the  tumor  given  30 
days  before  the  test  implantation.  Single  grafts  of  tumor  were  implanted 
by trocar; after various intervals  they were excised,  and a  portion reinjected 
into  the  strain  of origin of the  tumor,  to  test  their  viability.  Growth of the 
tumor on reinjection indicated survival of the test graft in the non-susceptible 
host.  The  proportions  of  grafts  viable  are  shown  in  Table  II.  The  median 
survival times of these homografts, calculated by probit analysis according to 
the procedure of Medawar (2), were as follows: 
SAI ~  C57BR/a  10.8 -4- 0.7 days 
SA1 --~ immunized C57BR/a  5.5 ~  0.4  " 
C1498 ~  B10.D2  10.5 -t- 0.6  " N. A.  ~n~CgrSON  161 
The  median  survival  times  (M.S.T.) in  the  non-~mmunized  hosts  are  in 
excellent agreement with  the M.S.T. of lymphosarcoma 6C3HED  in adult  A1 
mice found by the same method, 9.9 days (4), and also with the ~r.s.T.  of skin 
homografts among inbred mice strains, estimated by Billingham, Brent, Meda- 
war, and Sparrow (18) by a histological method:-- 
A --~ CBA  10.8 days 
CBA --, A  10.4  " 
A --, aaUU  9.0  " 
aaUU --, A  9.1  " 
C1498  carried  only a  single  tt-2 antigen  absent  in  B10.D2  mice,  so  that 
the  agreement  of its survival  time  with  the  other  donor-host  combinations 
shows  that  the H-2 antigens  are  singly as strong as any other antigen;  and 
that  when  two  or more  antigens  are  present  their  effects  are  not  additive. 
These survival times also show that the conditions of a  tumor homograft at 8 
days is an adequate  measure  of the degree of immunization  of the host, and 
this criterion was accordingly adopted in subsequent  experiments. 
The Duration  of the Power of the Regional Lymph Nodes  to Confer Immunity 
The ability of lymph nodes draining a  regressing tumor to confer immunity 
against the tumor was tested according to the experimental  design employed 
by Mitchison  (4)  and  by Billingham,  Brent,  and  Medawar  (6).  In order  to 
measure the time of origin and the duration of this power to confer immunity, 
groups of regional  nodes were  transferred,  at intervals  after  implantation  of 
the  graft  immunizing  the  donor.  Measurements  were made  after  implanting 
SA1  into  C57BR/a  hosts,  and  also  6C3HED  into  C57BL/10  hosts.  They 
were  also  made  after  reinjecting  SA1  into  previously  immunized  C57BR/a 
hosts, the second grafts being given 3 to 8 weeks after the first, and in the same 
area. 
The donors of the lymph nodes were implanted with tumor by trocar.  After the appro- 
priate interval, the prospective donors were bled immediately before the nodes were taken, 
so that the ability of their blood to confer passive immunity could be tested. Bleeding was 
by cardiac puncture into isotonic sodium citrate, the blood from each group of donors being 
pooled. A volume equivalent to 0.5 ml. whole blood was injected intraperituneally  into each 
of a group of mice of the same strain  as the donors. A second injection of the same amount 
was given 1 day later  from a portion  of the pool stored at 4°C. A second group of mice of 
the same strain  as  the donors  received the lymph nodes  draining  the immunizing graft, 
transferred  as mince at a dosage of 4 donors per host. A third group received the axillary, 
brachial,  and inguinal  nodes from the side of the donors  opposite the immunizing graft, 
transferred  in the same way and at the same dosage. A fourth group consisted of untreated 
mice of the same strain,  and a fifth of mice actively immunized by graft of tumor given at 
least  10 days earlier.  All five groups were injected  within  a few hours  after receiving the 
lymph node cells with a test graft of tumor in the flank. 8 days later  these grafts were ex- 
cised and a portion  implanted  subcutaneously  into the strain susceptible to the tumor,  to 
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The viability of the test grafts is shown in Table HI. The test grafts in the 
untreated control hosts showed a high viability, and in the actively immunized 
controls a low viability, as expected. In no case did the viability in the groups 
TABLE III 
Ability  of Cells from Draining Lympk Nodes to Confer Immunity; Failure of Contralateral 
Node Cells and Blood 
(a) Sal gn 2gan-lmmur~i~w.d  C57BR]a Hive 
Material transferred 
Draining lymph nodes ..................... 
Contrulateral lymph nodes ................ 
Whole blood ............................. 
Nil ..................................... 
Nil; actively immunized host .............. 
Interval between immunizing implantation of donors 
and transfer, days 
[  5  [,o1151  
Fraction of test grafts of tumor viable after 8 days 
in host 
10/10 
10/10 
9/9 
I0/I0 
0/10 
10/10 
10/10 
10/10 
0/10 
O/lO 
7/lO 
10/10 
lO/lO 
0/11 
10/10 
lO/lO 
1o/1o 
10/10 
O/lO 
9/9 
9/9 
10/10 
9/10 
0/10 
(b) Sa 1in Immun¢sed C57BR/a Mice 
Material transferred 
Draining lymph nodes. 
Contralateral lymph nodes. 
Nil.. 
Interval between restimuiating implantation of donor 
an  d transfer, days 
2  3  4  5  7  10 
3/s  3/15  1/5  7/10  0/5  5/s 
5/5  10/10  5/5  10/10  5/5  5/5 
5/5  14/15  10/10  10/10  10/10  5/5 
(¢) 6C3HED is Non-Im~n~  C57BL[10 Mi¢$ 
Material transferred 
Interval between immunizing unpiantatlon of donors 
and transfex, days 
Draining lymph nodes.. 
Contralateral lymph nodes... 
Whole blood 
Nil .... 
Nil; actively immunized host. 
lO/lO 
lO/lO 
10/10 
10/10 
2/10 
lO/lO 
8/lO 
6/13 
0/9 
7/9 
5/11 
o/13 
15 
8/10 
lO/lO 
811o 
7/1o 
1/lO 
receiving contralateral nodes, or blood, differ significantly from the untreated 
controls. The viability of test grafts in certain groups of hosts of transferred 
regional  nodes  was  lower  than  in  the  untreated  controls:  in  these  groups 
there is therefore evidence of transfer of immunity. 
The conclusion can be drawn,  that in C57BR/a  hosts after a  first graft of N.  A.  MITCHISON  153 
SA1, and also in C5?BL/10 hosts after a first graft of 6C3HED, the regional 
lymph nodes confer real immunity during  a  period which began between 3 
and 5 days, and ended between 10 and 15 days, after tumor implantation.  In 
C57BR/a hosts the power to confer immunity was revived between 0 and 2 
days, and declined between 7 and  10 days after a  resthnulating  injection of 
SA1,  although  the  power of the  regional  lymph nodes  to  confer immunity 
during  this  secondary response was not  so complete as after the initial  im- 
munization. At the doses transferred, the contmlateral nodes showed no power 
to confer immunity.  Nor did  the blood, either while the lymph nodes were 
active or later while serum antibody might have been expected to increase. 
iO0Olo. 
O/oimmunlzing  cJraf  t$ 
surviving 
0% 
IO0~b - 
°~o test  (Jr6f  ts 
killed  in seconder 
host.~ 04  lymph 
node  tens 
o% 
!  I  I 
/1'\'"  X" 
O  ' IO  20; 
I 
Interval  4fter  tumor  implantation  in  days 
F~o. 1. The survival time of grafts of SA1 in C57BR/a hosts; and the fim;.g of the abil- 
ity of the draining lymph node cells to confer immunity on secondary hosts. 
The weights of the regional  lymph nodes, reported in the succeeding paper 
(19), show by comparison with these results that the nodes can confer immunity 
only while they are markedly hypertrophied. The contralateral nodes showed 
slight hypertrophy, and their failure to confer immunity may therefore have 
been the result of transfer of insufficient cells. Tests of the power of the spleen to 
confer immunity also gave negative results, with the spleen taken 10 or 15 days 
after the immunizing  graft of tumor and transferred at a dosage of one spleen 
per host. Since Billingham,  Brent, and Medawar (6) have reported weak trans- 
fer of immunity with spleen,  this failure may also have been due to transfer of 
insufficient  cells. 
The data for SA1 in C57BR/a hosts from Tables II and HI are combined in 
fig. 1. It can be seen that the regional  lymph nodes were active in conferring 164  TMMUNOLOGICAL RESPONSE  TO  TUMOR  TRANSPLANTS.  I 
immunity during and immediately before the time of graft breakdown. During 
the secondary response a  relation was evident between the more rapid activa- 
tion of the regional lymph nodes and the earlier breakdown of the graft. 
Enhancing of Tumor Growth by Serum from Immunized Mice 
No inhibition of tumor growth was found in the secondary hosts receiving 
blood from immunized donors in the previous experiment, and in fact the test 
grafts appeared to grow more rapidly in these mice than in the controls. En- 
hanced growth of tumor cells  treated with isoimmune serum has indeed been 
mentioned by Gofer (20),  and serum from mice treated with lyophilized tissue 
has been reported to enhance the growth of tumor homografts by Kaliss, Molo- 
rout, Harriss, and Gault (21). A more pronounced enhancement of tumor growth 
was brought about by transfer of a  larger quantity of serum, in the following 
experiment:-- 
A group of C57BR/a mice were injected with SA1 by trocar, and bled after 15 days, at 
a time when the titre of hemaggintinating antibody in their serum was at a maximum (22). 
A pool of serum was prepared and stored at -20°C. Six C57BR/a mice were injected with 
SA1 by trocar, followed by 9 intraperitone'al injections of 0.5 ml. of the serum, given at 
intervals  of  2  days  commencing on  the  day  of  implantation.  Five out  of  these six 
mice showed progressive growth of the tumor, while 18 mice of the same strain injected at 
the same time sloughed the tumor off. 
This result confirms the relative inefficacy of serum as compared with lymph 
node cells in conferring immunity. 
The  Quantitative Relationship  between the Number of Cells Transferred and 
Immunity 
(a) Lymph Node Mince.-- 
Regional lymph nodes were minced and transferred into hosts of the same strain, from 
C57BR/a donors which 9 days before had  received an immunizing implantation of SA1. 
Dosages of 1, 2, and 4 donors per host were given. Test grafts of SA1 were then injected, 
and the effectiveness of the immunity conferred was measured in terms of the viability of 
these grafts after 8 days by the regraft test. 
TABLE IV 
Rdationship between Dosage of Lymph Node Mince and Immunity Conferred 
Immunity to Sal in C57BR/s mice. 
No, of donors  per host  Viability of test grafts of tumor after 8 days in host 
4  0/6 
2  s/6 
1  4/5 
o  7/10 N.  A.  MITCHISON  165 
The viabilities, as shown in Table IV, indicate that a  dosage of less than 3 
donors  per  host  was  insufficient to  confer  detectable  immunity. A  similar 
estimation of the effectiveness of transferred minced node is shown in Table HI 
of the succeeding paper (22), in which, as will be seen, a  more sensitive test 
detected the immunity conferred by a  dosage of 2 donors per host. 
(b) With Cell Suspensions.-- 
Suspensions of cells were transferred  to  hosts  of  the  same  strain,  from  the  regional 
nodes of C57BR/a  and C57BL/10 donors which 9 days before had received an immuui~.ing 
transplantation of SA1. Two  suspensions were transferred  in each strain,  each from  the 
TABLE V 
Relationship between Dosage of Lymph Node Cells and Immunity Conferred 
Immunity to Sal; 8 day old test tumors: weight in milli rams. 
~traJn of mouse. 
No. of. ceils/milliliter in  transferred  cell sus- 
l~nslon  ....... 
Vol. cell suspension transferred..  2 ml. 
1 ml. 
0.5 ml. 
0.25 ml. 
nil (control) 
C57BR/a 
25 X  10  e 
3+ 
12+ 
14+ 
15+ 
217+ 
279+ 
263 
306 
351 
544 
558 
48 X  10' 
2+ 
53+ 
193+ 
202+ 
114+ 
789 
CSTBL/IO 
63 X  I0  e 80X  I0~ 
61  31+ 
173  39+ 
68  14+ 
158  122 
127  34+ 
210  148 
105  110 
143  150 
83 
115 
110 
+, less than mean weight of controls: difference significant at 5 per cent level• 
nodes of 16 donors suspended in 8 ml. fluid. The numbers of ceils in each pool were counted 
and they are shown in Table V, where a transfer of 2 ml. cell suspension is equivalent to a 
dosage of 4 donors per host. A graded series of doses of cells was injected from each pool, 
pairs of hosts receiving 2, 1, 0.5, and 0.25 ml. cell suspension. During the C57BL/10 trans- 
fers the cells were washed by light centrifugation in the cold and resuspended in the original 
volume of Ringer solution. The two pools in each strain were run-  and tested together, with 
a common control group in which no lymph node cells were transferred. Immediately after 
transfer of the cells, each host received a subcutaneous transplantation of 1 X  106 ascltic 
cells of SA1, suspended in 0.1 ml. 8 days later the tumor growths were excised and weighed. 
This test of immunity proved slightly more sensitive than the regraft test. 
The  observed weights,  shown in Table V,  together  with  the  similar results 166  TM'~UNOLOGICAL  RESPONSE  TO  TUMOR  TRANSPLANTS.  I 
shown in  Table VII of the succeeding paper  (22),  show  that  the immunity 
becomes more pronounced as more cells are transferred. The minimum number 
of cells which produced an immunity detectable by this method was of the 
order of S0 X  10  e. 
Failure of Lympk Nodes to Give Rise to Tumors after Transplantation 
Lymph nodes draining the area of regression of a tumor have been repeatedly 
implanted in mice susceptible to the tumor, in order to test for the presence of 
viable  tumor  cells.  Regional  nodes  from  C57BR/a  mice  bearing  SA1  were 
transferred as  mince  into  A  hosts,  and  also  from  C57BL/10  mice  bearing 
6C3HED into C3H hosts, at 3, 5, 10, 15, and 20 days after tumor transplanta- 
tion. The transferred nodes never gave rise to tumors, in agreement with the 
results of similar transfers reported in an earlier paper (4). Unfortunately the 
possibility  of  antigen  transfer  is  not  eliminated  by  this  experiment,  since 
examples are known of tumor cells retaining their power to immunize while no 
longer capable of progressive growth (23, 24). 
Metastases of SA1 or 6C3HED into lymph nodes have not been found during 
the growth of these tumors in foreign strains,  except in the exceptional cases 
noted by Kaliss, Borges, and Day (25), during the growth of SA1  after pre- 
treatment of the host with lyophilized tissue. 
Failure of Tumor Cells Transplanted into the Peritoneum to Affect a Simultaneous 
Subcutaneous Graft 
Viable SA1  tissue was minced and transplanted by the same procedure as 
used  for lymph nodes into  the  peritoneum  of  CS7BR/a  hosts,  each mouse 
receiving approximately 0.1  ml. tissue. Test grafts of SA1 were then immedi- 
ately  transplanted  into  the flank.  6C3HED  was  transplanted  by  the  same 
procedure into  CS7BL/10 hosts.  In  neither case did  the proportion of  test 
grafts viable after 8 days, as judged by retransfer into the susceptible strain, 
differ significantly from the proportion in control groups which had  not been 
transplanted  with  tumor  in  the  peritoneum.  Thus  lymph  node  cells  must 
transfer an immunity which is effective earlier than the active immunity in- 
duced by tumor cells. 
Loss of Power of Lymph Node Cells to Confer Immunity after Freezing 
Lymph nodes from C$TBL/10 donors irrlmllnlzed  with 6C3HED were frozen at --20°C. 
for a few minutes and then transferred as mince at a dosage of 4 donors per host. This treat° 
ment abolished the power of the cells to confer immunity. The power of larger doses of 
frozen cells to transfer immunity was tested with the lymph nodes of A mice injected with 
$778. Regional and contralateral nodes were taken 9 days after implantation of the tumor. 
The nodes were transferred as mince into hosts of the same strain, or were rapidly frozen 
in a tube immersed in an alcohol-solid COl bath (-00°C.), thawed, homogenized in a ro- 
tating blade blender~ and transplanted into the peritoneum of hosts of the A strain. In order N. A.  ~xcmsoN  167 
to test for transferred immunity, a suspension of $778 cells were injected subcutaneously, 
and the resulting tumors weighed after 8 days. These weights are shown in Table VI. 
The untreated regional nodes conferred immunity, as was expected. But when 
transferred in large quantities after freezing, these nodes conferred no immunity 
and even appeared to enhance the growth of the tumor. Enhanced growth was 
also found in the group which received frozen contralateral nodes, and was no 
doubt due to serum antibody transferred with the nodes; injection of serum 
from immune mice has already been shown to enhance the growth of SA1. 
Transfer  of  Cells from  Donors  Immunized  against  an  Isoantigen,  into  //osts 
Carrying That Isoantigen 
The design of this experiment is shown in Fig. 2, in which four strains, and 
their genes at the histocompatibility-2 locus, are shown diagrammatically. At 
TABLE VI 
Loss of Power of Lymph Node Cells to Confer Immunity after Freezing 
$778 in A mice. 
8 day test tumor 
Transferred material  No. of donors  No. of l]osts  weights: mean and  per host  standard deviation 
Fresh regional nodes. 
Fresh contralateral nodes. 
Frozen regional  nodes. 
Frozen contralateral nodes. 
Nil. 
4 
4 
15 
7 
49  4-  24 
315  -4-  230 
459 :h  200 
495  -t-  115 
312  ±  99 
least  two pairs of strains are required, each pair isogenic except at  the 11-2 
locus, and with no strain susceptible to the tumors of any of the other. A tumor 
from the strain of genetic constitution//-2" was implanted in the//-2  b strain, 
the  two strains being isogenic except at  the//-2 locus.  The regional lymph 
nodes of the recipient then produced antibody against the//-2  ~ antigen alone. 
They were transferred into another pair of strains isogenic except at the//-2 
locus, of genetic constitutions 1t-2  ~ and//-2 ~. Each host was then implanted 
with test grafts of the tumor. Neither was susceptible, for although one of the 
hosts shared the//-2" antigen in common with the tumor, it differed from the 
tumor at other histocompatibility loci. In the case of the tt-2  ~ hosts, the trans- 
ferred nodes were expected to confer heightened resistance to the tumor, and 
this group therefore constituted a  control for the activity of the transferred 
lymph node cells. In the case of the//-2  ~ hosts receiving lymph node cells,  the 
expectation depended on the hypothesis adopted for the function of the trans- 
ferred cells.  If an antibody-producing  mechanism  was  transferred,  the//-2" 
antigen in the tissues of the host should have absorbed the antibody produced 168  IMMUNOLOGICAL I~ESPONSE TO  TUMOR TRANSPLANTS. I 
by the transferred ceils before it could reach the test grafts: heightened resist- 
ance to the tumor would then not be expected. If antigen was transferred, the 
simplest expectation would be that all the antigens of the tumor were  trans- 
ferred. Then,  although the H-2  ~ antigen could not have immunized the host, 
other antigens which could do so would be transferred: heightened resistance 
would be expected. However, only those tumor antigens which could immunize 
the donors may have entered their lymph node cells. If the tumor antigens were 
H-2~  1 
11  3 
~H  -£p  b 
I  /I  ~?\\  /I  I 
Fro. 2.  (1) A tumor from the H-2  ~ strain is implanted in the isogeaic H-2  b strain. (2) 
Lymph node tissue, producing anti-H-g" antibody, is transplanted into another pair of iso- 
genic strains, of groups of H-2  ~ and H-g'.  (3) Test grafts of the H-g  •  tumor are implanted 
in these hosts; the tumor grows temporarily in the H-g" but not in the H-g  ~ host. 
"sorted out" in this way in the donors, H-2 a antigen alone would be transferred, 
and heightened resistance would not be expected. 
Two series of experiments were can-ied out, as shown in Table VII. In one series B10.D2 
donors, corresponding  to the H-g  b donor strain in Fig. 2, were transplanted by trocar with 
C1498. 9 days later their regional lymph nodes were transferred as mince, into the strains 
shown, at a dosage of 4 donors per host. These hosts, together with an untreated control 
group from each strain, were then implanted by trocar with test grafts of C1498. 8 days 
later the test grafts were pall~ted, and the fractions which were positive to palpation are 
shown  in the table. Simple palpation, without regrafting to test viability, gave adequate 
discrimination between successful and unsuccessful transfer of immunity in this experiment. 
Each column in Table VII represents groups of mice tested at the same time, and with nodes N.  A.  ml"CHISON  169 
transferred from a  common group of donors. The B10.D2 group which received lymph node 
cells,  by comparison with their control group which did not receive cells, showed  that in 
both runs  the transferred cells possessed  the power  to  confer immunity.  The LP  group, 
with its control which did not receive cells, was the experimental group which carried the 
H-2 b antigen in its tissues, this antigen being the antigen against which the donors had been 
TABLE  VII 
Success of Transfer of Immunity  belween Donors and Hosts of Different Strains 
(a) Tr~r~fer of lymph Nods Cells from BIO.Dg (H-~) Donors Transplanle8 wilk C1498 (H-2  b) 
Host strain 
B10.D2 (H-2~).. 
BI0.D2 control. 
LP (H-Z  b) 
LP control. 
LP.RIII (isogenic  to  LP, not H-g~)... 
LP.RIII control. 
LP X LP.RIII F1 (H-gb)... 
LP X  LP.RIII F1 control. 
C1498 test grafts in hosts: proportion 
palpable after 8 days 
i 
0/4 
s/6 
2/2 
s/5 
0/s 
5/5 
0/5 
14/14 
5/5 
S/S 
0/S 
S/6 
5/S 
2/2 
Success of 
transfer 
+ 
+ 
(b) Tra~fer of Lymph Nod~ Cells  from C57BL/I0 (H-2  b) D~s  Transplanted witk Bll (H-2  d) 
Host strain  B11 test grafts in hosts:proportion  Succ¢-~ of 
palpable after 8 days  transfer 
C57BL/10 (H-2 b) ........................ 
C57BL/10 control ........................ 
B10.LP (isogenic to C57BL/10, tt-2 b) ....... 
B10.LP control .......................... 
B10.D2 (isogenic to C57BL/10, H-2 a) ...... 
B10.D2 control .......................... 
A  (H-2 d~) ............................... 
A control. 
A.Sw (isogenic to A, H-2  °) ................ 
A.Sw control ............................ 
DBA/2 (H-2 d) ........................... 
DBA/2 control .......................... 
D2.W (isogenic to DBA/2, not tt-2 d) ....... 
D2.W control ............................ 
0/5 
5/5 
0/3 
3/3 
2/2 
3/3 
s/5 
5/s 
0/5 
5/5 
5/5 
s/s 
0/5 
6/6 
+ 
+ 
+ 
+ 
immunized. The transferred cells had no effect in  this group.  The LP.RIII  group,  which 
were isogenic with LP,  constituted a  control in which the transferred cells did confer im- 
munity. The histocompatibllity group of LP-RM  has not been established, but it has been 
shown to differ from LP at the tt-2  locus. The F1 group possessed the H-2 b gene in single 
dosage, and this was sufficient to prevent transfer of immunity. 
In  the second series,  C57BL/10  cells were transferred from donors injected with Bll. 
The C57BL/IO group showed that the cells possessed the power to confer immunity. B10.LP 
is isogenic with C57BL/10 except at some unestablished locus other than H-2; it is not H-2  ~ 170  rM'acUNOLOGICAL RESPONSE  TO  TUMOR TRANSPLANTS.  I 
and accordingly the B10.LP hosts showed immunity. The H-2  = antigen of strain A produces 
the H-2  ~ antigen; H-2  ~ was the antigen against which the donors had been immunized, and 
the transferred cells accordingly had no effect in this group. The A.SW group, isogenic with 
A  except at  the H-2  locus,  constituted  a  control in which immunity was conferred.  Simi- 
larly DBA/2 is H-g  ~,  and  the cells had no effect in this group. The D2.W group, isogenic 
with DBA/2, was the control in which immunity was conferred. 
These results are in accord with the hypothesis that lymph node cells  con- 
ferred immunity by transferring an antibody-producing mechanism, and that 
the  antibody could be absorbed by the  tissues  of the host.  Alternately,  the 
immunity may have been induced by transferred antigen. If this is the case, 
the antigens must have been sorted in the donor, so that only those were trans- 
ferred which could immunize the donor. 
The Duration of Transferred Immunity 
The report in an earlier paper (4) that transferred immunity is of short dura- 
tion,  has  not been  confirmed by BiUingham,  Brent,  and Medawar  (6).  The 
duration  is  important  in  deciding  whether  antigen  is  transferred,  and  has 
accordingly been reinvestigated. 
The aim of the experiment was to compare the duration of three types of 
immunity; immunity actively induced by tumor grafts, ~mmunity transferred 
by lymph node cells  from donors into hosts of the  same inbred  strain,  and 
immunity transferred by lymph node cells into foreign hosts. 
Certain  diificulties beset any attempt to measure the duration of immunity trans- 
ferred into a foreign strain,  and a suitable combination of donor and host differing at 
the H-2 locus has not been found. An example of one obstacle is provided by the im- 
munity against C1498 transferred by B10.D2 cells into LP.RIII  hosts, in the previous 
experiment.  Cells from donors  immunized  with  the  tumor  conferred  adoptive im- 
munity; but  cells from  untreated  B10.D2  donors  could  confer  active  immunity. 
C57BL/10, the strain of origin of C1498, and B10.D2 are isogenic, so they must share 
several antigens  in common which are absent in LP.RIII mice: these antigens  pre- 
sumably induced the active immunity.  Since transferred  immunity was rapidly super- 
seded by active immunity,  its durations  could not be measured. Another obstacle has 
already  been found: the previous  experiment showed that cells do not transfer  im- 
munity if an antigen  of the tumor which the donor lacks is also present  in the host. 
For the reasons just given four pairs of strains which had slight histocompatibility dif- 
ferences were selected as donors and foreign hosts of transferred lymph node cells: BALB/ 
C -*  C.B6, C57BL/10 --~  C57L, B10.D2 ~  C57BL/lO-H-2  a,  and  C57BL/10-H-2  ~ --* 
B10.D2. Each of these pairs differed at one  or more histocompatibility loci, but not at the 
H-Z locus. Donors  from each strain were injected with SA1 by trocar. 9 days later the regional 
lymph nodes were transferred as mince out of each donor strain into an equal number of hosts 
of the same strain and of the paired foreign  strain, at a dosage  of 4 donors per host. Groups 
of mice of the donor strains, transplanted at the same time as they were retained as actively 
immunized controls. The immunity  was tested  at intervals, by injectingsubcutaneously 1 X 10  e 
ascitic cellsof  SA1 suspendedin0.1 ml., and weighing the resulting tumor growth after 8 days. N. A.  MITCmSON  171 
In each  series  tests  were  made together of equal numbers of mice: from  the group with 
active immunity; from the group of the donor strain with tranderred immunity; from the 
group of the foreign strain with transferred immunity; and from untreated control mice of 
the donor and foreign strains. The  mean and standard deviation of the test tumor weights 
from  each untreated control group were calculated.  A  difference  of more than twice the 
standard  deviation  (i.e.  significant at  the 5  per  cent  level) between  this mean and  the 
weight of a  test tumor in the experimental groups was taken as evidence of immunization. 
TABLE VIII 
Duration  of Immunity  to SaD Active Immunity:  Transferred  Iramunily  (Donors  and  Hosts 
of Same S~rain): and Transferred  Immunity (Foreign Hosts) 
Proportion of 8 day old test tumors with weights significantly different  (at 5 per cent 
level) from controls. 
C57BL/IO donors: CS?BL/IO, C$7J~ kosl$ 
Interval from active immunization,  or transfer 
of lymph  node cells, ~t  tumor implantation, 
Type of immunity 
Active  .....................................  2/21  [  12/21  I  ]2/212/212/2[  [ 
Transferred: same strain  .....................  12/2I[[2/21[12/2[1/212/3[0/3[014 
Transferred: foreign strain ...................  I2/2[  [  [2/21  I  11/210/2[0/2[  [ 
Balb/C donor: Balb/C, C.B6 hos~ 
Active  .....................................  [2/2  2/2  2/2 2/2 1/2 
Transferred: same strain .....................  2/2[  1/2  1/2 1/2 2/3 
Transferred: foreign strain ...................  2/2  2/2  2/2 0/2 2/2 
BIO.D2 donors: BIO.D2, C57BL/IO-H-2  d lwsts 
Active  .....................................  2/2  2/2  [2/2[2/2 3/3 
Transferred: same strain .....................  2/213/313/3[5/513/3 2/311/2[2/212/3 
Transferred: foreign strain ...................  2/2 3/3 3/3 1/5 1/3 1/2 0/2 0/2 
C57BL/IO-H-2  d donors: C57BL/IO-H-2  d, BIO.D2 ho$1s 
Transferred: same strain  ..... /:'. .............  2/4  2/4  [ 
Transferred: foreign strain.../  ................  2/4  0/4  I 
The proportions of immunized mice in the tested groups are shown in Table 
VIII.  The  numbers in each group  are  small,  but  the weights of the control 
tumors were sufficiently regular  to give significant  evidence of immunization. 
The data for the series with B10.D2 donors are also shown graphically in Fig. 3. 
The  active immunity appeared  to last over the full period of test in each 
series, except for one BALB/C mouse tested at 45 days. A  slight but reguarl 
progressive increase  in  the  test  tumor weights was noted in all  the actively 
immunized  series, indicating  a progressive decrease of immunity.  The rate of 
decrease varied among strains,  being most rapid for BALB/C. 172  ~NOLOGICAL RESPONSE TO TUMOR TRANSPLANTS. I 
In  the  series  with  C57BL/10 donors,  immunity resulting  from  transfer  of  cells 
within  the  strain  began  to  decline  after  15  to  30  days,  and  from  transfer  into  the 
foreign  strain  after  5 to 15 days.  With BI0.D2 donors, dec!ine  after  transfer 
2:0" 
C57BL~IO-H-2  d  hosts of 
5(0.02  lymph ~ode  celts  ---  ~  --- 
0  0  8(0.02  hosts  ot 
0  810.D2 lymph  ~ode  ¢ell~  O 
0  Actively  immunlzed 
BIO.D2 mice  T. 
W~ht  r4tio: 
test  tumor 
~nt~ tumors 
O 
/ 
/ 
/ 
/ 
1.0'  s  / 
0  / 
@/ 
/  @ 
/  0  ! 
/  0 
~  ii 
i  '~\/ 
O'S"  ~ 
I  O 
/8 
'  ' 20  '  30  45  ' 
~ratio~ of  immunity ia d6ys 
Fro. 3.  The duration of immunity: (1) conferred by lymph node cells from BI0.D2 do- 
nors transplanted  into B10.D2 hosts  (2) conferred by lymph node cells from B10.D2 donors 
transplanted  into C57BL/l~H-2  '~ hosts (3) active immunity in B10.D2 mice. 
Each point represents the ratio,  of the weight attained by a single test graft of SA1, to 
the mean weight  of control grafts of the tumor in untreated  mice; the lines run through 
the mean ratios. 
began within the strain after 7 to 10 days, and in the foreign strain after 3  to 
5 days. With C57BL/10-H-2  ~ donors, in the same strain no decline was appar- 
ent over 0 to 10 days, while in the foreign strain a decline was evident over this 
interval.  With BALB/C donors, the decline  within  the strain began rapidly, 
after 5 to 10 days, and even appeared to begin earlier than in the foreign strain, 
a  result which can be attributed  to errors of sampling. N.  A. MrrcmsoN  173 
Immunity transferred  within  a strain  was thus  of  long  duration,  particularly 
with  the C57BL/10  strain.  It  was  not  perceptibly  weaker  in  the  beginning than 
active  immunity, though presumably weaker  actually;  later  it  weakened faster 
than  active  immunity.  In  three  of  the  four  series,  the  immunity transferred  into 
foreign  hosts  weakened sooner  than  the  immunity transferred  within  the  strain. 
In the foreign  hosts the duration varied with the combination of donor and 
host,  none of  the  durations being outside  the  range of  survival  times of  homo- 
grafts.  The  immunity  still  evident  15  days after  C57BL/10  --~  C57L  and 
BALB/C ~  C.B6 transfers  was not unduly prolonged in view of the slight 
histocompatibility differences between donor and host. 
Following transfer of immunity by lymph node cells a  proportion of hosts 
still showed immunity after many weeks. At least in the cases of transfer into 
foreign strains, notably the two C.B6 hosts still  immunized 45 days after re- 
ceiving BALB/C nodes,  this immunity must  have been induced by antigen 
transferred with the cells. 
DISCUSSION 
Cells from the lymph nodes of immunized mice may have conferred trans- 
plantation immunity in several ways. The simplest explanation would be that 
tumor cells passed from the tumor into the lymph nodes of the donors, were 
transferred along with the lymph node cells, and induced active immunity in 
the host. This cannot have been the case in the present series of experiments; 
for the lymph nodes transplanted into mice susceptible to the tumors did not 
give rise to tumors, nor was active immunity induced by tumor cells effective as 
early as immunity conferred by lymph node cells. 
The  immunity  could hardly  have  been  conferred by preformed antibody 
carried by the cells and released into the serum of the host. If such preformed 
antibody was effective in combating grafts of tumor, it should have been de- 
tectable in the blood of the donors; yet whole blood and serum failed to transfer 
immunity. Furthermore the half-life of serum antibody was too short to account 
for the prolonged immunity conferred in some instances by transplanted cells. 
The  lymph  node  cells  may  have  been  immunologically  activated  before 
transfer, and could have conferred immunity by continuing to function in their 
host. This hypothesis is fully supported by the present observations. Immunity 
conferred in this way would be expected to develop earlier than active immu- 
nity, and to be lost if the cells were damaged by freezing.  If the cells produced 
their  effect through  cell-bound antibody or ~/a antibody manufactured  and 
released into the serum, an appropriate antigen in the host tissue would have 
blocked the effect. Transferred cells would be broken down by the homograft 
reaction of their host: this would account for the brief duration of immunity 
transferred into a foreign host. It would also account for the observation re- 
ported in the succeeding paper (22), that hemagglutinin production terminated 174  I~UNOLOGICAL  R~SPONSE  TO ~OR  TRANSPLANTS.  I 
earlier after transfer of lymph node ceils into a  foreign host than into a host of 
their strain of origin. Another observation reported  there  also  supports  the 
hypothesis that the transferred cells function autonomously: lymph node ceils 
from immunized and possibly also from normal donors conferred protection 
against tumor homografts on "pretreated mice," i.e. mice whose own ability to 
resist homografts had been blocked by pretreatment with frozen or lyophilized 
tissue. 
Material may also have passed from the transplanted lymph node cells into 
the cells of the host and activated them immunologically. The material which 
was passed over,  or "transduced," can be thought of either as transformed 
antigen or as an enzyme system for the manufacture of antibody; a logical dis- 
tinction between the two can hardly be drawn. Antigen from the graft presum- 
ably enters the ceils of the draining lymph nodes and elicits the production of 
antibody in them, so that the presence of such a system in these cells is likely. 
If this hypotheses were adopted, the present work would show that the trans- 
duced material induced immunity more rapidly than normal antigen, and that 
it could be inactivated by freezing. It would also show that only those tumor 
antigens which  could  immunize their host  are  converted  into  transducible 
material. These properties are plausible, but greater difficulty is presented by 
the additional evidence. The transduced material must have been eliminated 
more  rapidly in  foreign hosts,  and could induce immunity in  "pretreated" 
mice, whose own ability to  resist homografts had been blocked. These  two 
pieces of evidence, however, present less difficulty than might appear. A prece- 
dent can be found for a transduced enzyme system which retains the antigenic 
specificity of the donor and can be destroyed by the homograft reaction while 
in the cells of the host: the melanin production system in the guinea pig epi- 
dermis has been shown by Billingham and Medawar (26) to behave in this way. 
Treatment with lyophilized tissue is not effective in a  previously immunized 
animal (20),  so that the block in the immunological response must be in the 
setting up and not in the working of the antibody-producing mechanism. Con- 
sequently an antibody-producing mechanism introduced into pretreated ceils 
might not be blocked. 
Some of the present observations are analogous to observations already made 
in other systems of transfer of immunity by ceils. 
The rapid onset of antibody production  or sensitivity after cell transfer has been 
shown in the systems of Chase (9), of Fagreus and Grabar (10), and of Harris, Harris, 
and barber (11). Freezing and other agents which cause cell damage inhibit transfer 
in these systems, as also the transfer of transplantation immunity studied by Billing- 
ham, Brent, and Medawar (6). The transfer of lymph node ceils into pretreated mice 
is comparable with transfer into mice with actively acquired tolerance, accord!rig to 
the work of Billingham, Brent, and Medawar  (27); and with transfer  into rabbits 
treated with x-rays, in the work of Harris,  Harris,  Beale, and Smith (28). In these ~r.  A.  mrcmsoN  175 
cases the immunological  response of the host has been paralyzed, but graft resistance 
or serum antibody has appeared after the transfer of cells. 
In the studies of Chase, of Fagreus and Grabar, and of Harris, Harris, and Farber, 
cells were transferred between genetically non-uniform animals. In their donor-hosts 
relationship,  these experiments are  therefore comparable with  those in  the present 
work in which cells have been transferred from one inbred strain into another. In such 
cases the transferred immunity lasts only a few days. The more prolonged immunity 
noted after transfer within  the C37BL/10 and B10.D2  lines  in  the present work is 
similar to that reported after transfers of cells within the CBA  line by Billingham, 
Brent, and Medawar (6). 
There has been no general agreement on the function of the donated cells. Fagreus 
and Grabar (10) note the rapidity with which  transplanted spleen  tissue underwent 
breakdown, by a process which they interpret as a homograft reaction. They suggest 
that any enzyme system responsible for the production of antibody is transferred into 
the cells of the host. Harris, Harris, Beale, and Smith (28) note the contrast between 
the injurious  effect of x-rays on the host and the increased  effectiveness of ceils trans- 
ferred into an irradiated host, suggesting  that the host plays a purely passive role. 
In a  recent discussion  (9),  Chase has considered  the possibility of activation of the 
cells of the host. To explain the prolonged duration of transferred cutaneous sensitivity, 
when compared with the rapidity with which lymphocytes are thought to be lost, he 
points out that "cells may not have to survive for very long in order to initiate some 
process not yet understood." 
Jeter, Tremaine, and  Seebohm (29) have recently reported  that delayed hyper- 
sensitivity to 2,4-dinitrochlorobenzene  can be transferred by cells disintegrated  by 
sonic  vibration. Facts of this nature might provide decisive evidence for activation 
of host cells. 
SUMMARY 
The transfer of transplantation immunity by lymph node cells has been the 
subject of investigation. Transplantable tumors have been used to provoke and 
to measure transplantation immunity. Cells from the lymph nodes draining a 
tumor homograft were transferred as mince or in suspension into the peritoneum 
of a  secondary host  to  confer immunity.  These cells could  confer immunity 
while the immunizing graft was undergoing breakdown during the primary, and 
also during  the  more rapid  secondary,  response.  Cells from other nodes and 
from the spleen, and also whole blood or serum failed in these experiments to 
transfer immunity.  In one  combination  of tumor and  host,  serum from im- 
munized donors enhanced tumor growth. 
Evidence has been presented favoring the hypothesis that  the lymph node 
cells were immunologically activated before  transfer, and that they conferred 
immunity by continuing to function in their host. Immunization by tumor cells 
transferred along with the cells of the nodes could not account for the failure of 
lymph node transferred into susceptible animals to give rise to tumors; nor for 
the  failure of tumor cells to give rise  to immunity as rapidly as  transferred 176  I~I'UNOLOGICAL  RESPONSE  TO  TUMOR  TRANSPLANTS.  I 
lymph node  cells.  Freezing  and  thawing  of  the  transferred  ceils  prevented 
transfer of immunity. Cells from donors immunized against an isoantigen failed 
to confer immunity on hosts which carried that isoantigen, offering evidence of 
absorption of antibody. The duration of immunity transferred within an inbred 
strain was shorter than actively induced immunity, but longer than could have 
been expected of passively transferred immunity. After transfer of cells into 
foreign hosts, immunity declined more rapidly, as if the transferred ceils were 
destroyed by the homograft reaction of the host. 
The possibility that cells of the host were activated has also been discussed. A 
brief review showed that similar problems are raised in other systems of transfer 
of immunity by cells. 
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